Citius Oncology Inc
CTOR2.087USD
+0.027+1.33%
Market hours （ET）Quotes delayed by 15 min
USD0.000Pre-market (ET)
149.36MMarket Cap
LossP/E TTM
Citius Oncology Inc
2.087
+0.027+1.33%
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
Operating cash flows (indirect method)
Cash flow from continuing operating activities
--0.00
--0.00
412.72%684.15K
100.00%0.00
100.00%0.00
-356.09%-218.78K
---113.47K
---100.26K
---168.80K
---47.97K
Net income from continuing operations
-59.97%-7.74M
-40.86%-6.66M
-744.44%-6.66M
-884.61%-4.84M
-872.80%-4.73M
171.35%1.03M
--157.94K
--616.30K
--611.73K
--380.81K
Deferred tax
83.50%264.24K
83.50%264.24K
--264.24K
--144.00K
--144.00K
----
----
----
----
----
Change in working capital
96.84%5.38M
72.01%4.59M
-31133.58%-7.87M
2653.88%2.73M
12871.96%2.67M
-60.52%25.36K
--307.98K
--99.30K
---20.88K
--64.24K
-Change in inventory
---957.88K
---6.11M
---6.11M
----
----
----
----
----
----
----
-Change in prepaid expenses
----
--0.00
-3369.32%-1.08M
-3632.22%-1.17M
100.00%0.00
137.63%33.18K
--33.18K
--33.18K
---36.82K
---88.17K
-Change in other current liabilities
----
----
----
----
----
----
----
----
----
--126.42K
Cash from non-recurring investing activities
Cash from operating activities
--0.00
--0.00
412.72%684.15K
100.00%0.00
100.00%0.00
-356.09%-218.78K
---113.47K
---100.26K
---168.80K
---47.97K
Investing cash flow
Net cash flow from investment products
----
----
-3658.70%-24.81M
--68.64K
--24.74M
99.02%-660.00K
---660.00K
----
----
---67.32M
Net cash flow from other investing activities
----
----
---5.00M
----
----
----
----
----
----
----
Cash from non-current investing activities
Net cash flow from investing activities
----
----
-4416.28%-29.81M
--0.00
--0.00
99.02%-660.00K
---660.00K
----
----
---67.32M
Financing cash flow
Cash flow from continuous financing activities
----
----
3194.45%29.16M
-100.00%0.00
--0.00
-98.69%885.00K
--429.90K
--349.98K
----
--67.66M
Net cash flow from debt Issuance/repayment
----
----
2027.44%28.08M
--325.31K
--200.00K
1110.05%1.32M
----
----
----
---130.69K
Net cash flow from common stock issuance/repurchase
----
----
----
---268.64K
---24.94M
----
----
----
----
--66.03M
Net cash flow from other financing activities
----
----
346.82%1.07M
--207.73K
--192.27K
-124.68%-435.00K
--429.90K
----
----
--1.76M
Net cash from non-recurrent financing activities
Net cash from financing activities
----
----
3194.45%29.16M
-100.00%0.00
--0.00
-98.69%885.00K
--429.90K
--349.98K
----
--67.66M
Net cash flow
Beginning cash balance
--0.00
--112.00
-222.48%-32.48K
-100.00%0.00
-100.00%0.00
--26.52K
--370.10K
--120.38K
--289.18K
--0.00
Current period cash flow changes
--0.00
--0.00
423.81%32.60K
-100.00%0.00
100.00%0.00
-97.85%6.22K
---343.57K
--249.72K
---168.80K
--289.18K
Ending cash balance
--0.00
--112.00
-99.66%112.00
-100.00%0.00
-100.00%0.00
-88.68%32.75K
--26.52K
--370.10K
--120.38K
--289.18K
Free cash flow
----
----
412.72%684.15K
---366.11K
---191.69K
-356.09%-218.78K
---113.47K
----
----
---47.97K
Currency unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Audit opinions
--
--
--
--
--
--
--
--
--
--
